Drugs / SIR1-365
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04622332 | Dec 2020 → Nov 2021 | COVID-19 | Sironax USA, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIR1-365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622332 ↗ |
| Action | Inhibit | “inhibitor of RIPK1” PMID 39872839 ↗ Sep 2024 |
| Route | Oral | “Route of administration: oral” NCT04622332 ↗ |
| Target | RIPK1 | “inhibitor of RIPK1” PMID 39872839 ↗ Sep 2024 |